Which sponsor MSA insurance requirements are typically negotiable versus immovable?

Sponsor MSA insurance requirements look monolithic to operators reading them for the first time but in practice have substantial negotiability. The question is which elements major pharma sponsor legal departments treat as standard-of-the-house non-negotiable versus which they will accept reasonable alternatives for.

Limits are typically immovable. Additional insured wording, specific endorsement form numbers, notice-of-cancellation language, survival-of-coverage period, and certain specialty coverage requirements are typically negotiable to varying degrees.

Products liability limit floor — major pharma sponsors typically will not accept below their stated minimum ($5M, $10M, or $20M depending on the sponsor and product category).

Workers compensation statutory limits — required by law in any state where work is performed.

Commercial general liability $1M occurrence / $2M aggregate as floor — universally required and rarely an issue since operators carry this anyway.

Cyber liability for sponsors handling PHI or biospecimens — required floor levels vary by sponsor but the requirement itself is typically immovable.

Specific additional-insured form numbers — sponsor MSAs often reference CG 20 10 + CG 20 37 by name, but most sponsor legal departments will accept equivalent alternative forms (CG 20 33 with appropriate scope) if the operator's carrier issues those instead.

Notice of cancellation specific language — manuscript NOC endorsements vary by carrier; sponsor MSAs typically accept any 30-day notice form that satisfies the substantive requirement.

Recall extension specific language — if the products policy has FDA-recall extension wording, sponsor MSAs typically accept it even when the MSA specifies different recall-coverage language.

Specific carrier rating requirements — sponsor MSAs often require A.M. Best A-rated VII+; operators with carriers at A- VII or A- VIII can typically negotiate the rating requirement down with adequate justification.

Survival of insurance coverage post-termination — sponsor MSAs frequently demand 7+ years; operators can typically negotiate to 3-5 years with strong justification (product life cycle, statute-of-limitations alignment).

Mutual versus one-way indemnity — many sponsor MSAs start with one-way (operator indemnifies sponsor); mutual indemnity (operator and sponsor each indemnify for their own acts) is achievable for operators with leverage.

Aggregate-per-project endorsements — when an operator has multiple sponsor MSAs sharing the same products liability aggregate, per-project aggregate endorsements (preserving the full aggregate per project) are typically achievable from carriers and sometimes specifically required by sponsor MSAs.

Indemnity cap at insurance limits — operators with leverage can typically negotiate to cap indemnity obligations at the operator's actual insurance limits, eliminating the unlimited-personal-liability exposure that uncapped indemnity creates.

The insurance requirements section of a sponsor MSA is typically drafted by counsel without input from the sponsor's risk-management function — what looks like a hard requirement is often a default that the sponsor will accept reasonable modifications to. Operators with relationships at the sponsor's risk-management function (rather than just procurement or contract management) typically achieve more favorable terms.

For Texas operators, the negotiability question often resolves at the broker level — specialty brokers with deep sponsor-side relationships have visibility into which sponsor MSAs have flexible terms and which are truly immovable.